The B-cell lymphoma 2 antiapoptotic protein, BCL-2, also plays an important role in the intrinsic apoptosis pathway and has been shown to contribute to chemoresistance in many cancers (Yip and Reed, 2008), implying that targeting BCL-2 could have a potential role in the treatment of TNBC. Here, BCL2 is linked to cancer.